24/7 Market News Snapshot 28 February, 2025 – Longeveron Inc. Common Stock (NASDAQ:LGVN)

February 28, 2025

DENVER, Colo., 28 February, 2025 (247marketnews.com) – (NASDAQ:LGVN) are discussed in this article.
Longeveron Inc. has demonstrated exceptional momentum in recent trading sessions, witnessing a remarkable gain of 37.39%, with shares now trading at $2.102. Opening at $1.53, this robust performance has caught the attention of investors, boosted by a trading volume of 1.50 million shares, reflecting heightened market enthusiasm and demand. This surge underscores the potential for further growth and positions Longeveron as a key player in the biotechnology sector.

The company’s recent updates highlight significant progress in its clinical endeavors, particularly with the pivotal Phase 2b clinical trial, ELPIS II, aimed at investigating Lomecel-B™ as a treatment for Hypoplastic Left Heart Syndrome (HLHS). With enrollment exceeding 90%, the trial is on track for completion by the second quarter of 2025. A successful outcome could lead to a Biological License Application (BLA) submission anticipated in 2026, representing a major milestone for Longeveron and its therapeutic initiatives.

In terms of financial performance, Longeveron reported an impressive year-over-year revenue increase of 237% for 2024, totaling $2.4 million. This growth has been driven by the launch of its contract manufacturing services and increasing participation in the Bahamas Registry Trial, which focuses on frailty and cognitive impairment.

CEO Wa’el Hashad emphasized the company’s commitment to advancing investigational programs, with Lomecel-B™ poised to address both rare pediatric conditions and chronic illnesses, including Alzheimer’s disease. The recent approval of “laromestrocel” as its non-proprietary name by the World Health Organization further enhances the legitimacy of the therapy’s potential impact.

Looking ahead, Longeveron plans to engage with the FDA in early 2025 to discuss development pathways for Lomecel-B™ in mild Alzheimer’s, reaffirming its focus on meeting unmet medical needs. With considerable financial resources and a proactive approach to clinical trials, Longeveron is strategically positioned for transformative growth, aiming to improve patient outcomes across various health conditions.

Related news for (LGVN)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.